4-(2,6-difluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-amine derivatives as potentiators of HMRGX1 receptor for the treatment of pain
By developing pyrimidine compounds of hMrgX1 receptor enhancer, the dose restriction and addiction risk problems in existing chronic pain treatment methods have been solved, and effective treatment of chronic pain, diabetic peripheral nerve pain and osteoarthritis pain has been achieved. , and has good bioavailability and safety.
Patent Information
- Application Number
- CN202180046088.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-08
- Filing Date
- 2021-04-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-04-30
AI Technical Summary
Existing chronic pain treatments are dose-limiting and addictive risks, making it difficult to effectively treat chronic pain, especially pain associated with limited mobility and daily activities.
A compound as an enhancer for hMrgX1 receptors, including pyrimidine compounds of specific structures and their salts, was developed for the treatment of pain, reducing or eliminating pain symptoms by binding to hMrgX1 receptors, and providing pharmaceutical compositions and synthetic intermediates. to improve bioavailability.
The compound significantly reduces or eliminates pain, especially chronic pain, diabetic peripheral nerve pain and osteoarthritis pain, and has good bioavailability through oral routes, reducing the risk of addiction.
Smart Images

Figure CN115803321B_ABST
Abstract
Description
[0001] The present invention relates to compounds that are enhancers of hMrgX1 receptors, pharmaceutical compositions containing the compounds, methods for treating pain using the compounds, and intermediates and methods that can be used to synthesize the compounds.
[0002] It is estimated that approximately 20% of adults in the United States alone suffer from chronic pain. Chronic pain is one of the most common reasons for adults to seek medical care and is associated with limitations in mobility and daily activities. Unfortunately, chronic pain is often refractory to current therapies, and many analgesics are associated with dose-limiting adverse events or serious risks of addiction and abuse, which can be a significant barrier to their use in treating chronic pain. Therefore, there is an unmet need for new chronic pain therapies, particularly treatments that have reduced or effectively eliminated such adverse effects.
[0003] U.S. Patent No. 6,326,368B1 discloses certain 2-aryloxy- and 2-arylthio-substituted pyrimidines and triazines and their derivatives as corticotropin releasing factor (CRF) receptor antagonists, which can be used to treat various disorders such as depression, anxiety, drug addiction and inflammatory disorders. U.S. Patent No. 5,100,459 discloses certain substituted sulfonylureas and their intermediates. W. Wangdong, et al., ChemMedChem, Vol. 10(1), 57-61 (2015) discloses 2-(cyclopropanesulfonylamino)-N-(2-ethoxyphenyl)benzamide, ML382, as a potent and selective MrgX1 positive allosteric modulator.
[0004] There is a need for alternative treatments for pain, including chronic pain. Furthermore, there is a need for compounds that are enhancers of the hMrgX1 receptor.
[0005] Therefore, in one embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof:
[0006]
[0007] Where R 1 is hydrogen or methyl; and
[0008] R 2 yes:
[0009]
[0010] In one embodiment, R 1 It's hydrogen.
[0011] In one embodiment, R 1 It's methyl.
[0012] In one embodiment, R 2 yes:
[0013]
[0014] In one embodiment, R 2 yes:
[0015]
[0016] In one embodiment, R 2 yes:
[0017]
[0018] In a specific embodiment, the compound is:
[0019]
[0020] or a pharmaceutically acceptable salt thereof.
[0021] In a specific embodiment, the compound is:
[0022]
[0023] or a pharmaceutically acceptable salt thereof.
[0024] In a specific embodiment, the compound is:
[0025]
[0026] or a pharmaceutically acceptable salt thereof.
[0027] In a specific embodiment, the compound is:
[0028]
[0029] or a pharmaceutically acceptable salt thereof.
[0030] In a specific embodiment, the compound is:
[0031]
[0032] or a pharmaceutically acceptable salt thereof.
[0033] In a specific embodiment, the compound is:
[0034]
[0035] or a pharmaceutically acceptable salt thereof.
[0036] In one embodiment, the present invention also provides a method for treating pain in a patient in need of such treatment, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to the patient. In one embodiment, the present invention further provides a method for treating chronic pain in a patient in need of such treatment, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to the patient. In one embodiment, the present invention further provides a method for treating chronic low back pain in a patient in need of such treatment, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to the patient. In one embodiment, the present invention further provides a method for treating diabetic peripheral neuropathy in a patient in need of such treatment, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to the patient. In one embodiment, the present invention further provides a method for treating osteoarthritis pain in a patient in need of such treatment, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to the patient.
[0037] In one embodiment, the present invention further provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in therapy. In one embodiment, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in treating pain. In one embodiment, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in treating chronic pain.
[0038] In one embodiment, the present invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for treating pain. In one embodiment, the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for treating chronic pain.
[0039] In one embodiment, the present invention further provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. In one embodiment, the present invention further provides a method for preparing a pharmaceutical composition comprising mixing a compound of formula I or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents or excipients. In one embodiment, the present invention also includes novel intermediates and methods for synthesizing compounds of formula I.
[0040] As used herein, the terms "treating," "treatment," or "to treat" include inhibiting, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.
[0041] The term "patient" as used herein refers to a mammal, particularly a human.
[0042] As used herein, the term "effective amount" refers to that amount or dosage of a compound of the present invention or a pharmaceutically acceptable salt thereof, which provides the desired effect in a patient being diagnosed or treated following single or multiple dose administration to the patient.
[0043] The effective amount can be determined by one skilled in the art by using known techniques and by observing the results obtained under similar circumstances. In determining the effective amount for a patient, the attending diagnostician will consider many factors, including, but not limited to: the species of the patient; its size, age, and general health; the specific disease or disorder involved; the extent or involvement or severity of the disease or disorder; the response of the individual patient; the specific compound being administered; the mode of administration; the bioavailability characteristics of the administered preparation; the dosing regimen selected; the use of concomitant medications; and other relevant circumstances.
[0044] The compounds of the present invention are formulated into pharmaceutical compositions, which are administered by any route that makes the compounds bioavailable. Most preferably, such compositions are for oral administration. Such pharmaceutical compositions and methods for preparing them are well known in the art (see, e.g., Remington: The Science and Practice of Pharmacy, LV Allen, ed., 22nd ed., Pharmaceutical Press, 2012).
[0045] Certain intermediates described in the following preparations may contain one or more nitrogen protecting groups. It should be understood that, as will be appreciated by those skilled in the art, protecting groups may vary, depending on the specific reaction conditions and the specific transformation to be performed. Protection and deprotection conditions are well known to those skilled in the art and are described in the literature (see, for example, "Greene's Protective Groups in Organic Synthesis," 4th edition, Peter G.M. Wuts and Theodora W. Greene, John Wiley and Sons, Inc. 2007).
[0046] The pharmaceutically acceptable salts of the compounds of the present invention can be formed, for example, by reacting the appropriate free base of the compounds of the present invention with an appropriate pharmaceutically acceptable acid in a suitable solvent such as ether under standard conditions well known in the art. In addition, the formation of such pharmaceutically acceptable salts can occur simultaneously with the deprotection of the nitrogen protecting group. See, for example, Gould, PL, "Salt selection for basic drugs," International Journal of Pharmaceutics, 33: 201-217 (1986); Bastin, RJ, et al. "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities," Organic Process Research and Development, 4: 427-435 (2000); and Berge, SM, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66: 1-19, (1977).
[0047] Certain abbreviations are defined as follows: “ACN” refers to acetonitrile; “BAM8-22” refers to bovine adrenomedullary peptide 8-22; “Cat.#” refers to catalog number; “CRC” refers to concentration-response curve; “DMEM” refers to Dulbecco's modified Eagle's medium; “DMSO” refers to dimethyl sulfoxide; “DPBS” refers to Dulbecco's phosphate-buffered saline; “EC 50 "" refers to the effective concentration of the agent that gives a half-maximal response between baseline and maximum after the specified exposure time; "EDTA" refers to ethylenediaminetetraacetic acid; "ESMS" refers to electrospray mass spectrometry; "FBS" refers to fetal bovine serum; "g" refers to grams; "h" refers to hours; "HEC" refers to hydroxyethylcellulose; "HEK293" refers to human embryonic kidney 293 cells; "HEPES" refers to (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); "hMrgX1" refers to human MrgX1 receptor; "HTRF" refers to homogeneous time-resolved fluorescence; "IP1" refers to inositol monophosphate; "K p,uu” refers to the unbound brain / plasma partition coefficient; “LC-ESMS” refers to liquid chromatography-electrospray mass spectrometry; “min” refers to minutes; “mL” refers to milliliters; “Me” refers to methyl; “mol” refers to mole; “mmol” refers to millimole; “nm” refers to nanomole; “nmol” refers to nanomole; “m / z” refers to the mass-to-charge ratio for mass spectrometry; when in the context of biological data, “n” refers to the number of runs or experiments; “PBS” refers to phosphate-buffered saline; “rpm” refers to revolutions per minute; “SD” refers to standard deviation; “SEM” refers to standard error of the mean; and “U / mL” refers to units per milliliter.
[0048] General Chemistry
[0049] Compounds of the present invention or their salts can be prepared by a variety of procedures known to those of ordinary skill in the art, some of which are described in the following schemes, preparations and examples. It is recognized by those of ordinary skill in the art that the specific synthesis steps of each of the approaches can be combined in different ways or combined with steps from different schemes to prepare compounds of the present invention or their salts. By conventional methods well known in the art, including extraction, evaporation, precipitation, chromatography, filtration, grinding and crystallization, the product of each step in the following scheme can be recovered. In the following schemes, unless otherwise stated, all substituents are as defined above. Reagents and starting materials are easily available to those of ordinary skill in the art. The following schemes, preparations, examples and determinations further illustrate the present invention, but should not be interpreted as limiting the scope of the present invention in any way.
[0050] Solution 1
[0051]
[0052] Scheme 1 depicts the steps of converting a compound of Formula I (R 1 =H or CH3; R 2 =2,6-difluorophenyl, 2,4,6-trifluorophenyl or 4-cyano-2,6-difluorophenyl). In addition, compounds of Formula I can be prepared by transition metal (e.g., copper-, nickel- or palladium-mediated) cross coupling or Ullmann-type reactions as well described in the art.
[0053] 2-amino-6-trifluoromethyl-5-substituted pyrimidine starting materials with an appropriate leaving group (LG) at the 4-position (e.g., LG = Cl, Br, I, triflate, mesylate, tosylate) can be purchased commercially. Alternatively, one of ordinary skill in the art will recognize that 2-amino-6-trifluoromethyl-5-substituted pyrimidine starting materials can be obtained commercially with a suitable leaving group (LG) at the 4-position (e.g., LG = Cl, Br, I, triflate, mesylate, tosylate) under a variety of techniques well documented in the art, such as with an appropriate 5-substituted 4,4,4-trifluoro-2-methyl-3-oxo-butyrate (R 1 =H,CH3) to prepare appropriate starting materials. The subsequent conversion of the cyclized 2-amino-6-trifluoromethyl-4-hydroxy-5-substituted pyrimidine to the appropriate LG at the 4-position is well known to those of ordinary skill in the art.
[0054] Preparation and Examples
[0055] The following preparations and examples further illustrate the present invention and represent typical synthesis of compounds of the present invention. Reagents and starting materials are readily available or can be easily synthesized by one of ordinary skill in the art. It should be understood that the preparations and examples are provided by way of illustration rather than limitation, and that one of ordinary skill in the art may make various modifications.
[0056] exist LC-ES / MS was performed on a HP1100 liquid chromatography system. Electrospray mass spectrometry measurements were performed on a MassSelective Detector quadrupole mass spectrometer interfaced with a HP1100 HPLC. LC-MS conditions (low pH): Column: NX C18 2.1×50 mm 3.0 μm; Gradient: 5-100% B in 3 min, then 100% B for 0.75 min; Column temperature: 50°C ± 10°C; Flow rate: 1.2 mL / min; Solvent A: deionized water containing 0.1% HCOOH; Solvent B: ACN containing 0.1% formic acid; Wavelength 214 nm. Alternative LC-MS conditions (high pH): Column: MS C18 column 2.1×50 mm, 3.5 μm; Gradient: 5% solvent A for 0.25 min, gradient from 5% to 100% solvent B within 3 min and 100% solvent B for 0.5 min, or from 10% to 100% solvent B within 3 min and 100% solvent B for 0.75 min; Column temperature: 50℃±10℃; Flow rate: 1.2 mL / min; Solvent A: 10 mM NH4HCO3 pH 9; Solvent B: ACN; Wavelength: 214 nm.
[0057] Preparation 1
[0058] 4-(4-Bromo-2,6-difluoro-phenoxy)-6-(trifluoromethyl)pyrimidin-2-amine
[0059]
[0060] 2-Amino-4-chloro-6-(trifluoromethyl)pyrimidine (500 mg, 2.4 mmol) and 4-bromo-2,6-difluorophenol (616 mg, 2.9 mmol) were combined in a microwave vial and ACN (10 mL) was added. Potassium carbonate (665 mg, 4.8 mmol) was added, the vial was sealed, and heated at 160 ° C in a microwave reactor for 1 h. The reaction mixture was cooled, diluted with water, and extracted three times with ethyl acetate. The organic extracts were combined and dried over sodium sulfate. Filtered and the resulting filtrate was evaporated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel using a 5-100% gradient of ethyl acetate in hexanes to provide the title compound (789 mg, 89% yield) after solvent evaporation of the desired chromatographic fraction. ESMS (m / z, 79 Br / 81 Br): 370 / 372[M+H].
[0061] Preparation 2
[0062] 2-Amino-5-methyl-6-(trifluoromethyl)pyrimidin-4-ol
[0063]
[0064] A 25% solution of sodium methoxide in methanol (5.5 mL, 24 mmol) was added to a solution of ethyl 4,4,4-trifluoro-2-methyl-3-oxo-butyrate (4 g, 20 mmol) and guanidine (1.2 g, 20 mmol) in methanol (100 mL). Stir at room temperature for 23 h. The reaction mixture was evaporated under reduced pressure. The obtained white solid was dissolved in water (20 mL) and acidified with acetic acid (2 mL). The obtained product was collected by vacuum filtration, washed twice with water, and the obtained filter cake was dried under vacuum to obtain the title compound (2.3 g, 60% yield) as a white solid. ESMS (m / z): 194 [M+H].
[0065] Preparation 3
[0066] 4-Chloro-5-methyl-6-(trifluoromethyl)pyrimidin-2-amine
[0067]
[0068] In a microwave vial, phosphoryl chloride (5.5 mL, 59 mmol) was added to 2-amino-5-methyl-6-(trifluoromethyl)pyrimidine-4-ol (2.3 g, 11.9 mmol). The reaction mixture was heated at 110 °C for 30 min in a microwave reactor. The reaction mixture was poured onto ice, basified with 5M aqueous NaOH solution (50 mL), and extracted with ethyl acetate (100 mL). The combined extracts were dried over sodium sulfate, filtered, and the resulting filtrate was evaporated under reduced pressure. The resulting residue was dissolved in dichloromethane and purified by flash chromatography on silica gel, eluting with 10-25% ethyl acetate in hexanes to give the title compound (813 mg, 32% yield) as a white solid after evaporation of the desired chromatographic fraction. ESMS (m / z, 35 Cl / 37 Cl): 212 / 214 [M+H].
[0069] Preparation 4
[0070] 4-Chloro-5-iodo-6-(trifluoromethyl)pyrimidin-2-amine
[0071]
[0072] 4-Chloro-6-(trifluoromethyl)pyrimidine-2-amine (5 g, 25.2 mmol) in acetic acid (300 mL) was combined with N-iodosuccinimide (32.0 g, 138 mmol) at 0 ° C. The resulting mixture was heated and stirred at 70 ° C overnight. The reactant was cooled and quenched with water (120 mL). It was extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography to provide 4.8 g (53% yield) of the title product as a yellow solid. ES / MS m / z324[M+H] + .
[0073] Preparation 5
[0074] 4-((2-amino-5-iodo-6-(trifluoromethyl)pyrimidin-4-yl)oxy)-3,5-difluorobenzonitrile
[0075]
[0076] 4-Chloro-5-iodo-6-(trifluoromethyl)pyrimidine-2-amine (2.5 g, 7.0 mmol, 90 mass %) and 3,5-difluoro-4-hydroxy-benzonitrile (1.33 g, 8.49 mmol) were combined in DMF (35 mL) and potassium carbonate (2.88 g, 20.8 mmol) was added. The reaction mixture was heated at 90 ° C for 3 h. The reaction mixture was cooled and quenched with water (100 mL). It was extracted with ethyl acetate (60 mL x 2) and the combined organic layer was washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography to provide 2.6 g (76% yield) of the title product as a white solid. ES / MS m / z443[M+H] + .
[0077] Example 1
[0078] 4-(2,6-Difluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-amine
[0079]
[0080] In a microwave vial, potassium tert-butoxide (270 mg, 2.4 mmol) was added to a solution of 2-amino-4-chloro-6-(trifluoromethyl)pyrimidine (395 mg, 2.0 mmol) and 2,6-difluorophenol (289 mg, 2.2 mmol) in ACN (8.0 mL). The reaction mixture was heated at 120 ° C for 30 min in a microwave reactor. The reaction mixture was filtered through diatomaceous earth and the filtrate was evaporated under reduced pressure. The resulting residue was dissolved in dichloromethane containing a small amount of methanol, and the mixture was purified by flash chromatography on silica gel, eluting with a 5-20% gradient of ethyl acetate in hexanes to give the title compound (512 mg, 88% yield) as a white crystalline solid after solvent evaporation of the desired chromatographic fraction. ESMS (m / z): 292 [M+H].
[0081] Example 2
[0082] 4-(2,4,6-Trifluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-amine
[0083]
[0084] In a 500-mL round-bottom flask, potassium carbonate (26.9 g, 194.7 mmol) was added to a solution of 2-amino-4-chloro-6-(trifluoromethyl)pyrimidine (19.55 g, 97 mmol) and 2,4,6-trifluorophenol (15.2 g, 97.5 mmol) in N,N-dimethylformamide (200 mL). The reaction mixture was heated at 80 ° C for 16 h. The reaction mixture was quenched with water (500 mL) and extracted with ethyl acetate (2x500 mL). The combined organic extracts were washed with saturated NaCl aqueous solution (2x 800 mL), dried over sodium sulfate, filtered, and the resulting filtrate was concentrated under reduced pressure. The resulting residue was purified by flash chromatography over silica gel, eluted with a gradient of 0-37% ethyl acetate in petroleum ether, and the title compound (15.9 g, 53% yield) was obtained as a yellow solid after evaporation of the desired chromatographic fraction. ESMS (m / z): 310 [M+H].
[0085] Example 3
[0086] 4-[2-Amino-6-(trifluoromethyl)pyrimidin-4-yl]oxy-3,5-difluoro-benzonitrile
[0087]
[0088] Combine 4-(4-bromo-2,6-difluoro-phenoxy)-6-(trifluoromethyl)pyrimidin-2-amine (300 mg, 0.8 mmol), zinc cyanide (291 mg, 2.4 mmol), tetrakis(triphenylphosphine)palladium(0) (188 mg, 162 nmol) in a microwave vial and add N,N-dimethylformamide (6 mL). Seal the vial and heat to 100 °C in a heating block overnight. Cool the reaction, dilute with water, and extract three times with ethyl acetate. Combine the organic extracts and dry over sodium sulfate. Filter and evaporate the resulting filtrate under reduced pressure. The resulting residue is purified by flash chromatography on silica gel using a 5-100% gradient of ethyl acetate in hexanes to provide the title compound (200 mg, 78% yield) after solvent evaporation of the desired chromatographic fraction. ESMS (m / z): 317 [M+H].
[0089] Example 4
[0090] 5-Methyl-4-(trifluoromethyl)-6-(2,4,6-trifluorophenoxy)pyrimidin-2-amine
[0091]
[0092] In a microwave vial, potassium tert-butoxide (69 mg, 0.6 mmol) was added to a solution of 4-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-2-amine (106 mg, 0.5 mmol) and 2,4,6-trifluorophenol (84 mg, 0.6 mmol) in ACN (2.0 mL). The reaction mixture was heated at 120 °C for 30 min in a microwave reactor. The reaction mixture was filtered and the resulting filtrate was evaporated under a stream of air. The resulting residue was dissolved in 1:1 dichloromethane / methanol and purified by flash chromatography on silica gel, eluting with 5-10% ethyl acetate / hexanes to give the title compound (154 mg, 95% yield) as an off-white solid after solvent evaporation of the desired chromatographic fraction. ESMS (m / z): 324 [M+H].
[0093] Example 5
[0094] 4-[2-Amino-5-methyl-6-(trifluoromethyl)pyrimidin-4-yl]oxy-3,5-difluoro-benzonitrile
[0095]
[0096] 4-((2-amino-5-iodo-6-(trifluoromethyl)pyrimidin-4-yl)oxy)-3,5-difluorobenzonitrile (1.2 g, 2.4 mmol, 90% purity) and trimethylcyclotriboroxane (2.5 g, 10 mmol, 50% by mass) were combined in 1,4-dioxane (25 mL), and then cesium carbonate (2.4 g, 7.4 mmol) and tetrakis(triphenylphosphine)palladium(0) (580 mg, 0.486855 mmol) were added, and the reactants were heated to 120 ° C under nitrogen for 2 h. The reaction mixture was cooled and quenched with water (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic layers were combined and washed with brine (30 mL x 2). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was first purified by flash silica gel chromatography and then further purified by preparative HPLC (Instrument DD, method: column Xtimate C18 150*40mm*10um, conditions: water (10mM NH4HCO3)-ACN, start B 50%, end B 80%, with 10 minutes gradient time (min) 10, 100% B holding time (min) 2, flow rate 60mL / min). The effluent provided was combined, concentrated to remove most of the CH3CN, and then lyophilized to provide 481mg (60% yield) of the title compound as a white solid. ES / MS (m / z): 331 (M+H).
[0097] Example 6
[0098] 4-(2,6-Difluorophenoxy)-5-methyl-6-(trifluoromethyl)pyrimidin-2-amine
[0099]
[0100] In a microwave vial, potassium tert-butoxide (69 mg, 0.6 mmol) was added to a solution of 4-chloro-5-methyl-6-(trifluoromethyl)pyrimidin-2-amine (106 mg, 0.5 mmol) and 2,6-difluorophenol (72 mg, 0.6 mmol) in acetonitrile (2.0 mL). The reaction mixture was heated at 120 ° C for 30 min in a microwave reactor. The reaction mixture was filtered and the resulting filtrate was evaporated under air flow. The crude product was purified by reverse phase chromatography to give the title compound (124 mg, 81% yield) as a white solid. ESMS (m / z): 306 [M+H].
[0101] HTRF was used to determine the EC of hMrgX1 50 IP1 cell assay
[0102] Cell plating: Use growth medium containing DMEM and glutamine (GIBCO TM HEK293 cells stably expressing the recombinant human MrgX1 receptor were propagated in culture flasks (Corning, T150) with growth medium supplemented with 10% heat-inactivated FBS (HyCloneTM, catalog number CH30073), 1% penicillin / streptomycin (HyClone TM , catalog number SV30010; 10,000 U / mL penicillin; 10,000 μg / mL streptomycin in 0.85% NaCl), 20 mM HEPES (GIBCO TM , catalog number 15630122) and 0.3 mg / mL G418 (GIBCO TM When the cell monolayer reached a level of 80-90% confluence, the monolayer was washed with 10 mL of DPBS (HyClone TM , catalog number 14190-144) and washed once with TrypLE TM Express Enzymatic Cell Dissociation Medium (GIBCO TM , catalog number 12605-010) and diluted by adding 10 mL DPBS. The dissociated cells were transferred to a sterile 50 mL conical tube, pelleted by centrifugation at 300 x g to remove growth and dissociation medium, and diluted to 1 M cells / mL in DMEM for plating.
[0103] IP1 potency and efficacy determination: Test compounds were dissolved in DMSO to a concentration of 10 mM and serially diluted in DMSO to create a 10-point concentration response stock dilution plate. Growth medium was removed from the cell plate and the stock 10-point dilution plate was diluted into culture medium and stamped into the cell plate at a concentration of 2 times the final test concentration of 30 μM maximum. The endogenous agonist BAM8-22 ( Catalog No. 1763) was diluted to EC in cell plates. 15 (determined independently at a minimum of n=3) and incubated at room temperature for 120 min. Subsequently, half the volume of each of anti-IP1 cryptate and d2-labeled IP1 in lysis buffer supplied with the IP-One Gq Kit (CisBio catalog number 62IPAPEC) was added to the cell plate to initiate cell lysis and incubated in the dark at room temperature for 60 minutes. At this time, fluorescence was determined at 620 and 665 nm (~100 μs after laser excitation).
[0104] Data analysis: The fluorescence ratio was determined as the ratio of the fluorescence emission at 620 nm relative to that at 665 nm and converted to IP1 concentration using an IP1 standard curve generated in a separate plate according to the manufacturer's instructions. IP1 concentration was then plotted as a function of compound concentration. Enhancer potency (EC 50 ) is defined as the concentration of compound that is above the EC 15 The presence of α-peptide α results in an increase in IP1 concentration of 50% of that achieved by a saturating concentration of BAM8-22 and was determined using Genedata software (GeneData AG, Basel, Switzerland) which fits the following equation to a 10-point CRC, where y is the IP1 concentration determined for a given compound concentration, [L] represents the concentration of the test compound, and Max is the maximum increase achieved by a saturating concentration of BAM8-22:
[0105] Y=Max*[L] / (EC 50 +[L])
[0106] EC 50 Values are reported as geometric means (SEM, n) in nM.
[0107] Table 1. Relative EC of the compounds of Examples 1-6 for hMrgX1 IP-1 50
[0108] Example <![CDATA[Relative to EC 50 (SEM,n)(nM)]]> Max (mean + SEM) (nM) 1 72(30,4) 98+5.3,n=4 2 61(26,4) 109+9.2,n=4 3 104(26,13) 109+2.5,n=13 4 40(8,5) 125+7.9,n=5 5 82,n=1 120 6 38(3,3) 103+1.9,n=3 .
[0109] Table 1 shows the relative EC values achieved by the compounds of Examples 1 to 6 in the assay. 50and maximal stimulation, indicating that these compounds are enhancers of hMrgX1.
[0110] K in mice p,uu,脑 In vivo determination
[0111] Unbound brain / plasma partition coefficient (K p,uu,脑 ) is one of the key pharmacokinetic parameters used to evaluate the ability of a compound to cross the blood-brain barrier (BBB). It is usually measured in preclinical species using the following methodology. p,uu,脑 The values indicate the fraction of free drug in plasma that partitions across the BBB.
[0112] Subjects: The subjects for these studies were 12 male C57Bl / 6 mice (Envigo, Indianapolis, IN, USA) between 8-10 weeks of age at the time of the experiment. The mice were housed in groups of 4 in high-density plastic home cages. Food and water were available ad libitum. The room was maintained at 73°F and 30-70% relative humidity and kept on a light / dark cycle of 0600-1800 h.
[0113] Agent: 1% HEC, 0.25% 80, 0.05% DOWSIL TM The compound of Example 2 was prepared in vehicle at 0.3, 1 and 3 mg / ml. The prepared compound was sonicated in a water bath for 30 minutes until a suspension was formed. The mice were dosed with 3, 10 or 30 mg / kg at 10 ml / kg.
[0114] Dosage and tissue collection: For this experiment, four mice per dosing group received oral administration of the compound of Example 2 at 3, 10 or 30 mg / kg. Mice were euthanized by CO2 asphyxiation 2 h after dosing, plasma samples were collected by cardiac puncture, and mouse brains were removed, weighed and frozen on dry ice. Blood samples were stored in EDTA tubes on wet ice and centrifuged at 15k rpm for 10 min. Plasma was collected, plated in 96-well plates, and frozen at -80°C.
[0115] Pharmacokinetic Sampling: Plasma and brain samples obtained for Example 2 were analyzed using LC-MS / MS methods (Q2 Solutions, Indianapolis, IN, USA). Plasma samples were extracted using protein precipitation. The lower limit of quantification was 25 ng / mL, and the upper limit of quantification was 5000 ng / mL. Brain samples were homogenized and analytes were extracted using protein precipitation. The lower limit of quantification was 4 ng / g, and the upper limit of quantification was 200000 ng / g.
[0116] Determination of plasma and brain protein binding: Mouse plasma and brain homogenate protein binding was determined in vitro using equilibrium dialysis as described elsewhere [Zamek-Gliszczynski et al., J Pharm Sci, 101: 1932-1940, 2012]. Results are reported as plasma (f u,血浆 ) and brain (f u,脑 ) is then used to calculate K as follows p,uu,脑 The mouse of Example 2 u,血浆 and f u,脑 They were determined to be 0.0421 and 0.0181 respectively.
[0117] Analysis and Results: K at each time point was calculated from the following expression p,uu,脑 , where the individual components are derived from a combination of in vitro and in vivo measurements performed as described above:
[0118]
[0119] Among them C 总,脑 , C u,脑 , C 总,血浆 and C u,血浆 are the total and unbound brain and plasma concentrations, respectively, and f u,脑和 f u,血浆 are the unbound fractions in brain and plasma, respectively.
[0120] Table 2. Plasma and brain concentrations of Example 2 in mice following oral doses of 3, 10 and 30 mg / kg
[0121] * Using a mouse F of 0.0181 u,脑 The value and 0.0421 of ^ mouse f u,血浆 Value, as described above.
[0122] Unbound plasma concentrations and unbound brain concentrations showed dose-related increases in both plasma and brain, indicating that the compound of Example 2 crosses the blood-brain barrier and has central penetrance in mice 2 h after oral administration. There appears to be a dose balance in plasma and brain exposure across dose groups. The average unbound brain to unbound plasma ratio (Kp,uu-brain) of the compound of Example 2 ranged from 0.506±0.1 to 0.601±0.0553 (mean±SD, n=4 per group); indicating that the active transport mechanism does not work in the brain tissue of mice.
Claims
1. A compound of the following formula or a pharmaceutically acceptable salt thereof: Where R 1 is hydrogen or methyl; and R 2 yes:
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 It's hydrogen.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 It's methyl.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 yes:
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 yes:
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 yes:
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
8. The compound according to claim 7, which is:
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
10. The compound according to claim 9, which is:
11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
12. The compound according to claim 11, which is:
13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
14. The compound according to claim 13, which is:
15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
16. The compound according to claim 15, which is:
17. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is:
18. The compound according to claim 17, wherein the compound is:
19. Use of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of pain.
20. Use of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of chronic pain.
21. Use of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating chronic low back pain.
22. Use of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating diabetic peripheral neuropathy.
23. Use of a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of osteoarthritis pain.
24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
25. A method for preparing a pharmaceutical composition, comprising mixing a compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents or excipients.
Citation Information
Patent Citations
Process for glueing materials
EP0000418A1
Substituted sulfonylureas
US5100459A
Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6326368B1
Chemical comkpounds
GB0021494D0
Chemical Compounds
US20120010183A1
